P L Zinzani

Summary

Affiliation: University of Bologna
Country: Italy

Publications

  1. ncbi Clinical experience with fludarabine in indolent non-Hodgkin's lymphoma
    Pier Luigi Zinzani
    Istituto di Ematologia e Oncologia Medica Seragnoli, Universita di Bologna, Bologna, Italy
    Hematol J 5:S38-49. 2004
  2. ncbi High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Italy
    Leuk Lymphoma 45:321-6. 2004
  3. ncbi Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma
    Pier Luigi Zinzani
    Seràgnoli Institute of Hematology and Medical Oncology, University of Bologna, Bologna, Italy
    Cancer 100:2190-4. 2004
  4. ncbi Role of anemia in survival of patients with elderly aggressive non-Hodgkin's lymphoma after chemotherapy
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna
    Leuk Lymphoma 46:1449-54. 2005
  5. ncbi Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma
    Pier Luigi Zinzani
    Institute of Hematology and Oncology L and A Seragnoli, University of Bologna, Italy
    Clin Lymphoma Myeloma 7:291-5. 2007
  6. ncbi Rituximab in primary conjunctiva lymphoma
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    Leuk Res 29:107-8. 2005
  7. ncbi Complications of cytotoxic chemotherapy in older patients: focus on myelotoxicity in lymphomas
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology, L eA Seràgnoli, University of Bologna, Policlinico S Orsola, Via Massarenti 9, 40138 Bologna, Italy
    Crit Rev Oncol Hematol 48:S27-31. 2003
  8. ncbi Extranodal marginal zone B-cell lymphoma of MALT-type of the lung: single-center experience with 12 patients
    Pier Luigi Zinzani
    Institute of Hematology and Oncology L e A Seràgnoli, University of Bologna, Bologna, Italy
    Leuk Lymphoma 44:821-4. 2003
  9. ncbi High-dose therapy with autologous transplantation for Hodgkin's disease: the Bologna experience
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology, L e A Seragnoli, University of Bologna, Italy
    Haematologica 88:522-8. 2003
  10. ncbi Ifosfamide, epirubicin and etoposide (IEV) in non-Hodgkin's lymphoma and Hodgkin's disease: the Italian experience
    P L Zinzani
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Italy
    Ann Oncol 14:i43-5. 2003

Detail Information

Publications114 found, 100 shown here

  1. ncbi Clinical experience with fludarabine in indolent non-Hodgkin's lymphoma
    Pier Luigi Zinzani
    Istituto di Ematologia e Oncologia Medica Seragnoli, Universita di Bologna, Bologna, Italy
    Hematol J 5:S38-49. 2004
    ..Available clinical data therefore indicate that fludarabine has an important role to play in the treatment of patients with indolent NHL. Further, studies are warranted to identify the optimal fludarabine regimen for this patient group...
  2. ncbi High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Italy
    Leuk Lymphoma 45:321-6. 2004
    ..Improved patient selection, transplant timing, ongoing improvements in supportive care, and selected phase III trials should increase outcomes further...
  3. ncbi Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma
    Pier Luigi Zinzani
    Seràgnoli Institute of Hematology and Medical Oncology, University of Bologna, Bologna, Italy
    Cancer 100:2190-4. 2004
    ....
  4. ncbi Role of anemia in survival of patients with elderly aggressive non-Hodgkin's lymphoma after chemotherapy
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna
    Leuk Lymphoma 46:1449-54. 2005
    ..985; p = 0.049). Post-treatment hemoglobin values appear to provide a strong independent predictor of 5-year survival in elderly aggressive NHL, supporting the potential role of anemia correction in this group of patients...
  5. ncbi Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma
    Pier Luigi Zinzani
    Institute of Hematology and Oncology L and A Seragnoli, University of Bologna, Italy
    Clin Lymphoma Myeloma 7:291-5. 2007
    ..The purpose of this study was to evaluate the reliability of positron emission tomography (PET) in patients with follicular lymphoma (FL) after induction treatment...
  6. ncbi Rituximab in primary conjunctiva lymphoma
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    Leuk Res 29:107-8. 2005
    ..Our experience with a patient with a primary conjunctiva lymphoma who was treated with conventional dose of rituximab obtaining a complete response without acute and late local toxicity for the eye...
  7. ncbi Complications of cytotoxic chemotherapy in older patients: focus on myelotoxicity in lymphomas
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology, L eA Seràgnoli, University of Bologna, Policlinico S Orsola, Via Massarenti 9, 40138 Bologna, Italy
    Crit Rev Oncol Hematol 48:S27-31. 2003
    ..The research of specific therapeutic protocols is needed to cure the elderly lymphoma patients reducing the risk of important toxic effects...
  8. ncbi Extranodal marginal zone B-cell lymphoma of MALT-type of the lung: single-center experience with 12 patients
    Pier Luigi Zinzani
    Institute of Hematology and Oncology L e A Seràgnoli, University of Bologna, Bologna, Italy
    Leuk Lymphoma 44:821-4. 2003
    ..In conclusion, these data underline the diagnostic utility of BAL and the therapeutic efficacy of a chemotherapeutic strategy based on regimens such as N-CVP in the context of localized MALT lymphoma of the lung...
  9. ncbi High-dose therapy with autologous transplantation for Hodgkin's disease: the Bologna experience
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology, L e A Seragnoli, University of Bologna, Italy
    Haematologica 88:522-8. 2003
    ..In this work we examine the characteristics and outcome of patients with Hodgkin's disease (HD) treated with high-dose therapy (HDT) and autologous transplantation at our Institute between 1982 to 2000...
  10. ncbi Ifosfamide, epirubicin and etoposide (IEV) in non-Hodgkin's lymphoma and Hodgkin's disease: the Italian experience
    P L Zinzani
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Italy
    Ann Oncol 14:i43-5. 2003
  11. ncbi Salvage chemotherapy in follicular non-Hodgkin's lymphoma: focus on tolerability
    Pier Luigi Zinzani
    Institute of Hematology and Oncology Seragnoli, University of Bologna, Italy
    Clin Lymphoma Myeloma 7:115-24. 2006
    ..These could include the use of more efficient preparative and purging approaches in the transplantation setting or the administration of rituximab maintenance therapy after (immuno) chemotherapy induction or transplantation...
  12. ncbi Primary bone lymphoma: experience with 52 patients
    Pier Luigi Zinzani
    Istituto di Ematologia e Oncologia Medica L and A Seragnoli, Policlinico S Orsola, Via Massarenti 9, 40138 Bologna, Italy
    Haematologica 88:280-5. 2003
    ..A retrospective analysis was performed to assess the efficacy of various treatments of non-Hodgkin's primary bone lymphomas (PBL)...
  13. ncbi Thoughts on the eradication of Helicobacter pylori infection in localized gastric mucosa-associated lymphoid tissue lymphoma
    Pier Luigi Zinzani
    Institute of Hematology and Oncology Seragnoli, University of Bologna, Italy
    Leuk Lymphoma 47:2013-4. 2006
  14. ncbi Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma
    Pier Luigi Zinzani
    Institute of Hematology and Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
    Haematologica 92:771-7. 2007
    ..The aim of this retrospective study was to verify the reliability of positive PET scans of the mediastinum in following up patients with mediastinal lymphoma, using histological findings as a comparison...
  15. ncbi Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Italy
    Haematologica 87:1258-64. 2002
    ....
  16. ncbi Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma
    Pier Luigi Zinzani
    Institute of Hematology and Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
    J Clin Oncol 25:4293-7. 2007
    ..To determine the antitumor activity of the proteasome inhibitor bortezomib in patients with cutaneous T-cell lymphoma (CTCL) or peripheral T-cell lymphoma unspecified (PTCLU) with isolated skin involvement...
  17. ncbi Mycosis fungoides
    Pier Luigi Zinzani
    L and A Seragnoli Institute of Hematology and Oncology, University of Bologna, Bologna, Italy
    Crit Rev Oncol Hematol 65:172-82. 2008
    ....
  18. ncbi Primary gastric diffuse large-cell lymphoma
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology, L and A Seragnoli, University of Bologna, Bologna, Italy
    Leuk Lymphoma 47:1201-2. 2006
  19. ncbi Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas
    Pier Luigi Zinzani
    Institute of Hematology and Oncology Seragnoli, University of Bologna, Bologna, Italy
    J Clin Oncol 24:1376-82. 2006
    ..Primary cutaneous B-cell lymphomas (PCBCLs) are a distinct group of primary cutaneous lymphomas with few and conflicting data on their prognostic factors...
  20. ncbi Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays
    Pier Luigi Zinzani
    Pathologic Anatomy and Lymphoma Unit, Institute of Haematology and Medical Oncology L and A Seragnoli, Bologna University, Bologna, Italy
    Haematologica 90:341-7. 2005
    ..Patients with diffuse large B-cell lymphoma (DLBCL) could benefit from integration of well-established bioclinical prognostic factors with new tools - such as micro-arrays - exploring aberrant gene and/or protein expression...
  21. ncbi Lymphoma: diagnosis, staging, natural history, and treatment strategies
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology, L e A Seragnoli, University of Bologna, Italy
    Semin Oncol 32:S4-10. 2005
    ..Strategies using various chemotherapy combinations, including innovative agents such as 90 Y-ibritumomab tiuxetan, show promise in the treatment of NHL, particularly indolent NHL, and hopefully will lead to an improvement in prognosis...
  22. pmc Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients
    P L Zinzani
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Italy
    Br J Cancer 91:850-4. 2004
    ..PET negativity at restaging strongly suggests the absence of active disease; histopathological verification is important in patients who show PET positivity...
  23. ncbi Effectiveness of fludarabine, idarubicin and cyclophosphamide (FLUIC) combination regimen for young patients with untreated non-follicular low-grade non-Hodgkin's lymphoma
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    Leuk Lymphoma 45:1815-9. 2004
    ..These preliminary data suggest that FLUIC is a very active, well-tolerated regimen for young, untreated patients with advanced non-follicular LG-NHL...
  24. ncbi Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Italy
    J Clin Oncol 22:2654-61. 2004
    ..We performed a randomized comparative trial of FM with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) front-line chemotherapy with and without sequential rituximab...
  25. ncbi Traditional treatment approaches in B-cell non-Hodgkin's lymphoma
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology, L e A Seragnoli, University of Bologna, Italy
    Leuk Lymphoma 44:S6-14. 2003
    ..At present, for patients with untreated disseminated disease; recurrent disease; or high-grade disease in the presence of poor risk factors; alternative treatment strategies are needed...
  26. ncbi Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Italy
    Haematologica 89:309-13. 2004
    ..Although remission of hairy cell leukemia (HCL) after treatment with 2-chlorodeoxyadenosine (2-CdA) appears to be long lasting, few reports currently provide results from follow-up exceeding 5 years...
  27. ncbi Autologous hematopoietic stem cell transplantation in Non-Hodgkin's lymphomas
    Pier Luigi Zinzani
    L and A Seragnoli Institute of Hematology and Oncology, University of Bologna, Bologna, Italy
    Acta Haematol 114:255-9. 2005
    ..In the last decade, autologous hematopoietic stem cell transplantation has played an important role in front-line and salvage treatments of indolent and aggressive NHL...
  28. ncbi Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients
    P L Zinzani
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, and Nuclear Medicine, S Orsola Hospital, Italy
    Ann Oncol 17:1296-300. 2006
    ..It is important to distinguish between responders to standard treatment and non-responders Hodgkin's disease (HD) patients...
  29. ncbi Bronchus-associated lymphoid tissue lymphomas: an update of a rare extranodal maltoma
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology, L and A Seragnoli, University of Bologna, Italy
    Clin Lymphoma Myeloma 7:566-72. 2007
    ..The purpose of this review is to point out the state of the art regarding bronchus-associated lymphoid tissues lymphomas in terms of etiology, pathogenesis, clinics, and therapeutics, including our single-center experience of 23 cases...
  30. doi A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
    Cancer 112:856-62. 2008
    ....
  31. ncbi Primary mediastinal large B-cell lymphoma with sclerosis: a clinical study of 89 patients treated with MACOP-B chemotherapy and radiation therapy
    P L Zinzani
    Istituto di Ematologia e Oncologia Medica Seragnoli, Policlinico S Orsola, Via Massarenti 9, 40138 Bologna Italy
    Haematologica 86:187-91. 2001
    ..Primary mediastinal large B-cell lymphoma (PMLBCL) with sclerosis has recently been recognized as a specific clinical and pathologic entity for which the best therapeutic approach seems to be a combination of chemotherapy and radiotherapy...
  32. ncbi Long-term follow-up after fludarabine treatment in pretreated patients with chronic lymphocytic leukemia
    P L Zinzani
    Istituto di Ematologia e Oncologia Medica Seragnoli, Policlinico S Orsola, Via Massarenti 9, 40121 Bologna, Italy
    Haematologica 85:1135-9. 2000
    ..A study update to assess long-term survival following fludarabine salvage treatment in previously treated patients with chronic lymphocytic lymphoma (CLL)...
  33. ncbi Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients
    P L Zinzani
    Istituto di Ematologia e Oncologia Medica Seragnoli, Policlinico S Orsola, Via Massarenti 9, 40138 Bologna, Italy
    Haematologica 85:926-9. 2000
    ..To assess the efficacy and the toxic profile of gemcitabine, a novel pyrimidine antimetabolite active against several solid tumors, we carried out a study in heavily pretreated Hodgkin's disease (HD) patients...
  34. ncbi Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine
    P L Zinzani
    Istituto di Ematologia e Oncologia Medica Seragnoli, Policlinico S Orsola, Via Massarenti 9, 40138 Bologna, Italy
    Haematologica 85:922-5. 2000
    ..Thus, it is important to evaluate such long-term outcome data in order to increase understanding of the efficacy of this agent in the management of HCL...
  35. ncbi Efficacy of the VBM regimen in the treatment of elderly patients with Hodgkin's disease
    P L Zinzani
    Istituto di Ematologia e Oncologia Medica Seragnoli, Policlinico S Orsola, Via Massarenti 9, 40138 Bologna Italy
    Haematologica 85:729-32. 2000
    ..We investigated the therapeutic efficacy and toxicity of the three-drug-combination VBM (vinblastine, bleomycin, and methotrexate) regimen in a group of 19 elderly HD patients...
  36. ncbi Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients
    P L Zinzani
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, and Institute of Dermatology Immacolata, Rome, Italy
    J Clin Oncol 18:2603-6. 2000
    ..To evaluate the efficacy and toxicity of gemcitabine, a novel pyrimidine antimetabolite with a low-toxicity profile and activity in several solid tumors, in patients with relapsed or refractory cutaneous T-cell lymphomas...
  37. ncbi Efficacy of fludarabine and mitoxantrone (FN) combination regimen in untreated indolent non-Hodgkin's lymphomas
    P L Zinzani
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Italy
    Ann Oncol 11:363-5. 2000
    ..The aim of this study was to define the therapeutic efficacy and toxicity of a combination of FLU and mitoxantrone (FN regimen) in untreated LG-NHL...
  38. ncbi Efficacy of vinorelbine, epirubicin and prednisone combination regimen in pretreated elderly patients with aggressive non-Hodgkin's lymphoma
    P L Zinzani
    Istituto di Ematologia e Oncologia Medica Seragnoli, Policlinico S Orsola, Via Massarenti 9, 40121 Bologna, Italy
    Haematologica 86:287-90. 2001
    ....
  39. ncbi Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma
    P L Zinzani
    Institute of Hematology and Medical Oncology and University of Bologna, Bologna, Italy
    J Clin Oncol 18:773-9. 2000
    ..A first comparative trial of fludarabine (FLU) alone versus FLU plus idarubicin (FLU-ID) for indolent or mantle-cell lymphomas...
  40. ncbi Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients
    P L Zinzani
    Institute of Hematology Seragnoli, University of Bologna, Bologna
    Ann Oncol 13:1364-9. 2002
    ..Here we report a prospective, multicenter, randomized trial comparing the efficacy and toxicity of 8- and 12-week regimens of VNCOP-B plus G-CSF...
  41. doi Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop
    Pier Luigi Zinzani
    Institute of Hematology and Oncology Seragnoli, Via Massarenti 9, 40138 Bologna, Italy
    Eur J Cancer 44:366-73. 2008
    ..This approach would maximise the therapeutic potential of this agent by encouraging its use early in the disease course of follicular lymphomas...
  42. ncbi Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients
    Pier Luigi Zinzani
    Istituto di Ematologia e Oncologia Medica L e A Seragnoli, Policlinico S Orsola, Via Massarenti 9, 40138 Bologna, Italy
    Haematologica 87:816-21. 2002
    ..We adopted the strategy of using salvage chemotherapy to debulk disease and simultaneously mobilize stem cells, using a regimen based on ifosfamide and etoposide, (drugs not usually used for front-line treatment)...
  43. ncbi Advantages of positron emission tomography (PET) with respect to computed tomography in the follow-up of lymphoma patients with abdominal presentation
    P L Zinzani
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Italy
    Leuk Lymphoma 43:1239-43. 2002
    ..PET restaging is very valuable for the identification of patients who would need appropriate second-line therapy because of the presence of residual active abdominal disease and should be made widely available in combination with CT...
  44. doi A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients
    P L Zinzani
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
    Ann Oncol 19:769-73. 2008
    ....
  45. doi Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ)
    Pier Luigi Zinzani
    Institute of Haematology and Medical Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
    Lancet Oncol 9:352-8. 2008
    ....
  46. doi Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma
    Pier Luigi Zinzani
    Institute of Hematology and Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
    J Clin Oncol 27:1781-7. 2009
    ..However, there are no prospective studies investigating the value of serial FDG-PET over time in patients in complete remission...
  47. ncbi MACOP-B regimen followed by involved-field radiation therapy in early-stage aggressive non-Hodgkin's lymphoma patients: 14-year update results
    P L Zinzani
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Italy
    Leuk Lymphoma 42:989-95. 2001
    ..MACOP-B regimen with/without involved-field radiation therapy provides a safe and effective combined modality treatment for early-stage aggressive NHL, with the possibility to definitively cure two thirds of the patients...
  48. ncbi Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease
    P L Zinzani
    Institute of Hematology, L e A Seragnoli, University of Bologna, Italy
    Haematologica 79:508-12. 1994
    ..Ideally, the cytotoxic agents should lack complete cross resistance with those utilized up front...
  49. ncbi Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients
    P L Zinzani
    Institute of Hematology and Oncology Seragnoli, Roma, Italy
    J Clin Oncol 16:1532-7. 1998
    ..In particular, soluble CD30 (sCD30) levels were elevated in most patients with Hodgkin's disease (HD) and anaplastic large-cell lymphoma (ALCL)...
  50. ncbi CEP regimen (CCNU, etoposide, prednimustine) for relapsed/refractory Hodgkin's disease
    P L Zinzani
    Institute of Hematology, L e A Seragnoli, University of Bologna, Italy
    Tumori 80:438-42. 1994
    ..Although initial treatment of Hodgkin's disease induces a complete remission in most patients, approximately 50% of patients with advanced disease will not achieve a complete remission or will relapse following the first complete remission...
  51. ncbi The role of positron emission tomography (PET) in the management of lymphoma patients
    P L Zinzani
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Italy
    Ann Oncol 10:1181-4. 1999
    ..We investigated the ability of fluorine-18 fluorodeoxyglucose positron emission tomography (PET) to differentiate between residual active tumor tissue and fibrosis...
  52. doi MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients
    E Derenzini
    Department of Haematology and Medical Oncology, University of Bologna, Bologna, Italy
    Ann Oncol 21:1173-8. 2010
    ..Adult Langerhans cell histiocytosis (LCH) is a rare disease. The combination of vinblastine and prednisone, given in a 6-month course, is the standard of care but prospective randomized trials are lacking...
  53. doi Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma
    Enrico Derenzini
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
    Cancer 113:2496-503. 2008
    ....
  54. doi Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome
    P L Zinzani
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Via Massarenti 9, Bologna, Italy
    Ann Oncol 21:860-3. 2010
    ..Gemcitabine should be considered a suitable option. We report the long-term update of 39 pretreated T-cell lymphoma patients treated with gemcitabine...
  55. ncbi The pathologist's view point. Part II --aggressive lymphomas
    S A Pileri
    Service of Pathologic Anatomy and Hematopathology, Institute of Hematology and Oncology L and A Seragnoli, Bologna University, Policlinico S Orsola, Italy
    Haematologica 85:1308-21. 2000
    ..The authors focus on the key features of aggressive B- and T-cell lymphomas, aiming to contribute to the cross-talk between pathologists and clinicians...
  56. ncbi CEOP regimen in the treatment of advanced low-grade non-Hodgkin's lymphomas: preliminary report
    P L Zinzani
    Institute of Hematology L. e A. Sergnoli, University of Bologna, Italy
    Tumori 76:533-6. 1990
    ..Clinical and hematologic toxicities were irrelevant. This regimen was effective in inducing a good remission rate of low-grade NHL, but a longer follow-up for definitive conclusions is warranted...
  57. doi A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by ⁹⁰Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma
    P L Zinzani
    Institute of Hematology and Medical Oncology L e A Seràgnoli, Policlinico Sant Orsola Malpighi, University of Bologna, Bologna, Italy
    Ann Oncol 23:415-20. 2012
    ....
  58. ncbi The pathologist's view point. Part I--indolent lymphomas
    S A Pileri
    Service of Pathologic Anatomy and Haematopathology, Institute Hematology and Oncology L and A Seràgnoli, Bologna University, Policlinico S Orsola, Italy
    Haematologica 85:1291-307. 2000
    ..The authors focus on the key features of B-cell lymphomas with an indolent behavior, aiming to contribute to the cross-talk between pathologists and clinicians...
  59. ncbi Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification
    S A Pileri
    Chair of Pathologic Anatomy and Lymphoma Unit, L and A Seràgnoli Institute of Haematology and Clinical Oncology, Bologna University, Via Massarenti 9, 40138 Bologna, Italy
    Histopathology 41:482-509. 2002
    ..The more recent acquisitions on the pathobiology of DLBCLs are reviewed in the light of the authors' experience, aiming to contribute to the existing debate on the topic...
  60. doi Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma
    Enrico Derenzini
    Institute of Haematology and Medical Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
    Leuk Lymphoma 50:1824-9. 2009
    ..R-MACOP-B regimen followed by involved-field radiation on bulky presentation is safe and very effective in the treatment of young patients with low-risk DLBCL...
  61. ncbi Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients
    P L Zinzani
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    J Clin Oncol 17:1254. 1999
    ..We report a retrospective analysis of 75 patients with nongastrointestinal low-grade MALT lymphoma, presenting their clinical, therapeutic, and follow-up data with respect to the initial location of the lymphoma...
  62. ncbi VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly
    Mariapaola Fina
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
    Leuk Lymphoma 48:2167-71. 2007
    ..Three CRs relapsed within 12 months from the completion of treatment. Clinical and hematological toxicity was moderate. This regimen was effective in inducing a good remission rate with moderate toxic effects in elderly DLBCL patients...
  63. ncbi Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score
    Philip Went
    Institute of Hematology and Clinical Oncology L and A Seràgnoli, Hematology and Hematopathology Units, St Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    J Clin Oncol 24:2472-9. 2006
    ..We evaluated the expression of 19 markers in 148 PTCLs/U and 45 PTCLs of the angioimmunoblastic type (AILD)...
  64. pmc Myeloperoxidase expression by histiocytes in Kikuchi's and Kikuchi-like lymphadenopathy
    S A Pileri
    Pathology and Clinical Units, Institute of Hematology and Clinical Oncology L and A Seràgnoli, Bologna University, Bologna, Italy
    Am J Pathol 159:915-24. 2001
    ....
  65. pmc Primary follicular lymphoma of the testis in childhood: an entity with peculiar clinical and molecular characteristics
    S A Pileri
    Pathology and Clinical Units of the Institute of Haematology and Clinical Oncology L and A Seràgnoli, University of Bologna, Italy
    J Clin Pathol 55:684-8. 2002
    ..The aim of this study was to characterise a PPFLT arising in a 4 year old boy...
  66. ncbi The importance of endoscopic ultrasonography in the management of low-grade gastric mucosa-associated lymphoid tissue lymphoma
    G Caletti
    Department of Internal Medicine and Gastroenterology, University of Bologna, Italy
    Aliment Pharmacol Ther 16:1715-22. 2002
    ..However, in some patients, these lesions persist despite antibiotic treatment...
  67. ncbi In vitro study of the combination gemcitabine + fludarabine on freshly isolated chronic lymphocytic leukemia cells
    P Tosi
    Istituto di Ematologia ed Oncologia Medica L e A Seràgnoli, Policlinico S Orsola, Via Massarenti, 9, 40138 Bologna, Italy
    Haematologica 84:794-8. 1999
    ..In this study we evaluated the effects of the combination of fludarabine and gemcitabine, a deoxycytidine analog that has shown both in vitro and in vivo activity against a variety of solid tumors...
  68. ncbi Difficult diagnostic and therapeutic cases: CASE 1. true thymic hyperplasia in a patient treated for T-cell lymphoma
    Stefano Ascani
    Unit of Hematopathology, Institute of Hematology and Clinical Oncology L and A Seràgnoli, Bologna University, Bologna, Italy
    J Clin Oncol 22:953-4. 2004
  69. ncbi 18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma
    Lapo Alinari
    Institute of Hematology and Oncology Seragnoli, University of Bologna, Italy
    Leuk Lymphoma 47:2096-101. 2006
    ..Sensitivity of 18F FDG-PET for extra-nodal MALT was 81%. The data show that 18FDG-PET is a useful diagnostic tool in order to stage, restage or monitor disease in patients with extra-nodal MALT lymphoma...
  70. pmc Hodgkin's lymphoma: the pathologist's viewpoint
    S A Pileri
    Pathologic Anatomy and Haematopathology, Bologna University, Policlinico S Orsola, Via Massarenti 9, 40138 Bologna, Italy
    J Clin Pathol 55:162-76. 2002
    ..Treatments adjusted to the pathobiological characteristics of the tumour in at risk patients have been proposed and are on the way to being applied...
  71. ncbi Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients
    S A Pileri
    Institute of Hematology and Clinical Oncology L and A Seràgnoli, University of Bologna, Bologna, Italy
    Leukemia 21:340-50. 2007
    ....
  72. ncbi Posttransplant lymphoproliferative disorders in liver transplanted patients: a report of four cases
    S Lorenzini
    Department of Internal Medicine, Cardioangiology and Hepatology, University of Bologna, and Department of Gastroenterology and Internal Medicine, Orsola Malpighi Hospital, Bologna, Italy
    Transplant Proc 38:1477-80. 2006
    ..They are often the result of Epstein-Barr virus (EBV)-induced proliferation of B-lymphocytes in the setting of immunosuppression...
  73. ncbi Indolent lymphoma: the pathologist's viewpoint
    S A Pileri
    Pathologic Anatomy and Unit of Haematopathology, Institute of Haematology and Clinical Oncology L and A Seràgnoli, Bologna University, Bologna, Italy
    Ann Oncol 15:12-8. 2004
    ..The recent identification of the IRTA gene family corresponding to IG-like receptors differentially expressed in B-cells might contribute to their better understanding...
  74. ncbi The conjugate Rituximab/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with Fludarabine
    L Polito
    Dipartimento di Patologia Sperimentale, Universita di Bologna, Bologna, Italy
    Leukemia 18:1215-22. 2004
    ..Moreover, sensitivity of Raji to Rituximab/saporin-S6 was augmented when cells were coincubated with Fludarabine. The synergistic toxic effect of the two drugs led to a total elimination of the neoplastic population...
  75. ncbi Genomic imbalances associated with secondary acute leukemias in Hodgkin lymphoma
    Gianluca Brusa
    Istituto di Ematologia e Oncologia Medica Lorenzo e Ariosto Serágnoli, Università di Bologna Medical School, 40138 Bologna, Italy
    Oncol Rep 18:1427-34. 2007
    ..Immunohistochemistry confirmed aCGH results and distinguished the distribution of either amplified or deleted gene products in neoplastic Reed Sternberg (RS) cells and non-neoplastic lymph node components...
  76. doi Biology and treatment of follicular lymphoma
    Pier Paolo Piccaluga
    Molecular Pathology Laboratory, Hematopathology Unit, Department of Hematology and Oncological Sciences L and A Seràgnoli, S Orsola Malpighi Hospital, University of Bologna, Via Massarenti 9, Bologna, Italy
    Expert Rev Hematol 2:533-47. 2009
    ..Novel approaches, including stem cell transplantation, monoclonal antibodies and innovative agents, should be then considered for improving long-term results...
  77. ncbi Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation
    Pier Paolo Piccaluga
    Institute of Hematology and Medical Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Cancer Res 67:10703-10. 2007
    ..Our study provides new relevant information on AILT biology and new candidates for possible therapeutic targets such as PDGFRA (platelet-derived growth factor alpha) and VEGF...
  78. doi Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology L e A Seràgnoli, Policlinico Sant Orsola Malpighi, University of Bologna, Bologna, Italy
    Cancer 117:1010-8. 2011
    ....
  79. doi Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology L e A Seràgnoli, Policlinico Sant Orsola Malpighi, University of Bologna, Bologna, Italy
    Cancer 116:5667-75. 2010
    ..This study investigated the role of immunohistochemical discrimination between GCB and ABC&NC-DLBCL subtypes in identifying those high-risk patients who may benefit from a more aggressive first-line therapeutic approach...
  80. doi Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Bologna, Italy
    Clin Lymphoma Myeloma Leuk 10:258-61. 2010
    ..Based on historical data on the role of radioimmunotherapy (RIT) in pretreated non-Hodgkin lymphoma, we reviewed our hospital's clinical database...
  81. doi Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas
    Pier Paolo Piccaluga
    Molecular Pathology Laboratory, Unit of Hematopathology, Department of Hematology and Oncology, L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Via Massarenti, 9, 40138 Bologna, Italy
    Haematologica 93:1033-8. 2008
    ..Follicular lymphomas are currently subdivided into grades I, II, IIIa and IIIb. This distinction is, however, questioned...
  82. doi Early relapse in a patient with Hodgkin's disease and negative interim FDG-PET
    Stefano Fanti
    Unità Operativa di Medicina Nucleare, Padiglione 30, Azienda Ospedaliero Universitaria di Bologna, Policlinico S Orsola Malpighi, Via Massarenti 9, 40138 Bologna, Italy
    Ann Nucl Med 22:429-32. 2008
    ..This case testifies the possibility of early relapse of lymphoma even in the case of negative interim PET; it also supports the usefulness of end-treatment PET scan in lymphoma patients...
  83. doi Clinical significance of axillary findings in patients with lymphoma during follow-up with 18F-fluorodeoxyglucose-PET
    Charoula S Tsamita
    Department of Nuclear Medicine, Institute of Emathology, Policlinico S Orsola Malpighi, Bologna, Italy
    Nucl Med Commun 29:705-10. 2008
    ..The aim of this study was to evaluate the clinical significance of positive axillary findings in patients with Hodgkin's disease and non-Hodgkin's lymphoma during follow-up with 18F-fluorodeoxyglucose-PET...
  84. doi Hairy cell leukemia: evaluation of the long-term outcome in 121 patients
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Bologna, Italy
    Cancer 116:4788-92. 2010
    ..Recently, purine analogues (pentostatin and cladribine) changed radically the treatment modality, inducing complete and durable responses in the majority of patients...
  85. ncbi Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology L e A Seràgnoli, Policlinico Sant Orsola Malpighi, University of Bologna, Via Massarenti 9, Bologna, Italy
    Clin Cancer Res 16:3998-4004. 2010
    ....
  86. doi Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study
    Pier Luigi Zinzani
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Italy
    Clin Lymphoma Myeloma 9:381-5. 2009
    ..Recently, the superiority of R-CHOP (rituximab plus cyclophosphamide/doxorubicin/vincristine/ prednisone) over CHOP-like regimens has been demonstrated in elderly and younger patients with low-risk diffuse large B-cell lymphoma...
  87. doi High-dose therapy and stem cell transplantation
    Pier Luigi Zinzani
    University of Bologna, Bologna, Italy
    Semin Hematol 47:S15-7. 2010
    ..However, it is unclear whether there is a role for allogeneic transplant as a frontline treatment option...
  88. ncbi Diffuse large B-cell lymphoma (DLBCL), anaplastic variant. report on a problematic case primarily arising in the stomach
    Stefano Aldo Pileri
    Pathologic Anatomy, Clinical and Pathology Lymphoma Units, Institute of Haematology and Clinical Oncology L and A Seràgnoli, Bologna University, Italy
    Haematologica 87:ECR40. 2002
  89. ncbi Primary cardiac non-Hodgkin lymphoma presenting with atrial flutter and pericardial effusion
    Pier Paolo Piccaluga
    Institute of Haematology and Medical Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Br J Haematol 134:356. 2006
  90. pmc Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets
    Pier Paolo Piccaluga
    Institute of Hematology and Medical Oncology L and A Seragnoli, Sant Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    J Clin Invest 117:823-34. 2007
    ..These results, which might be extended to other more rare PTCL categories, provide insight into tumor pathogenesis and clinical management of PTCL/U...
  91. ncbi Expression of platelet-derived growth factor receptor alpha in peripheral T-cell lymphoma not otherwise specified
    Pier Paolo Piccaluga
    Institute for Cancer Genetics, Columbia University, New York, NY, USA
    Lancet Oncol 6:440. 2005
  92. pmc Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins
    Stefano A Pileri
    Istituto di Ematologia e Oncologia Medica, L e A Seràgnoli Unità Cliniche e di Anatomia Patologica, Universita di Bologna, Bologna, Italy
    Am J Pathol 162:243-53. 2003
    ..However, it differs from other aggressive B-cell lymphomas in that it shows defective immunoglobulin production despite the expression of OCT-2, BOB.1, and PU.1 transcription factors and the lack of IgV(H) gene crippling mutations...
  93. ncbi Histopathology of B-cell chronic lymphocytic leukemia
    Stefano A Pileri
    Unit of Haematopathology, Institute of Haematology and Clinical Oncology L and A Seràgnoli, Bologna University, Via Massarenti 9, 40138 Bologna, Italy
    Hematol Oncol Clin North Am 18:807-26, viii. 2004
    ..The relevance of the examination of trephines and surgical specimens is outlined with special reference to the identification of risk factors in individual patients...
  94. ncbi The development of more than one histologic type of lymphoma in the same patient is frequent and confers a worse prognosis
    Stefano A Pileri
    Lymphoma Study Group, Institute of Haematology and Clinical Oncology, Bologna University, Italy
    Haematologica 90:293. 2005
  95. ncbi Non-Hodgkin's lymphoma: the evolving role of purine analogues
    Pier Luigi Zinzani
    Institute of Haematology and Medical Oncology L e A Seragnoli, University of Bologna, Bologna, Italy
    Best Pract Res Clin Haematol 15:505-16. 2002
    ..Within the last decade they have moved from salvage therapy to front-line studies. Further insight into the mechanism of action of the purine analogues will to lead to further advances in this group of diseases...
  96. ncbi Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients
    Enrica Marchi
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    Cancer 104:2437-41. 2005
    ....
  97. pmc B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens
    Elena Sabattini
    Haemolymphopathology Service, St Orsola Hospital, University of Bologna, Bologna, Italy
    J Clin Pathol 60:627-32. 2007
    ..The expression of zeta-associated protein 70 (ZAP70) is significantly associated with the more aggressive unmutated forms...
  98. ncbi Consensus conference on the management of tumor lysis syndrome
    Patrizia Tosi
    Hematology Unit, Istituto Seragnoli, Ospedale Sant Orsola Malpighi, Bologna, Italy
    Haematologica 93:1877-85. 2008
    ..In conclusion, the Panel recommended rasburicase for tumor lysis syndrome prophylaxis in selected patients based on the drug efficacy profile. Methodologically rigorous studies are needed to clarify its cost-effectiveness profile...
  99. ncbi Rituximab in heavily pretreated cutaneous B-cell lymphoma
    Pier Luigi Zinzani
    Leuk Lymphoma 44:1637-8. 2003
  100. ncbi Expression of CD52 in peripheral T-cell lymphoma
    Pier Paolo Piccaluga
    Haematologica 92:566-7. 2007
    ....
  101. ncbi Leukocyte-specific phosphoprotein-1 and PU.1: two useful markers for distinguishing T-cell-rich B-cell lymphoma from lymphocyte-predominant Hodgkin's disease
    Teresa Marafioti
    Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom
    Haematologica 89:957-64. 2004
    ..In this paper, we have evaluated the usefulness of the pan-leukocyte marker LSP1 and the transcription factor PU.1 for resolving such diagnostic problems...